SGLT2 Inhibitors as First‑Line Therapy for Adults with Type 2 Diabetes and Chronic Kidney Disease

Guideline Recommendations

• The KDIGO 2020 guideline gives a Grade 1A (highest level) recommendation for using SGLT2 inhibitors in adults with type 2 diabetes, chronic kidney disease (CKD) and an estimated glomerular filtration rate (eGFR) ≥ 30 mL/min/1.73 m². 1
• The 2024 BMJ guideline panel issues a strong recommendation for SGLT2 inhibitors in all adults at high or very‑high risk of CKD progression and related complications, regardless of diabetes status. 2
• The Mayo Clinic 2022 guideline states that SGLT2 inhibitors (or GLP‑1 receptor agonists) should be prescribed irrespective of baseline HbA1c, with preference for agents that have proven kidney or cardiovascular benefit. 3

Clinical Benefits of SGLT2 Inhibitors

• In patients with CKD, SGLT2 inhibitors reduce all‑cause mortality, cardiovascular mortality, hospitalization for heart failure, progression to kidney failure, non‑fatal myocardial infarction, and non‑fatal stroke. 2
• These agents provide cardiorenal protection that is independent of glucose‑lowering effects, making them the cornerstone of therapy for adults with type 2 diabetes and CKD. [3][2]1

Lipid‑Management Recommendations (Non‑SGLT2 Options)

• Fibrates are not recommended in the treatment algorithm for adults with type 2 diabetes and CKD. [3][1]
• Lipid control should focus on high‑intensity statin therapy, with the addition of ezetimibe if LDL‑cholesterol targets are not achieved. The KDIGO guideline recommends statin ± ezetimibe for patients ≥ 50 years with CKD. 3
• Although ezetimibe is appropriate for lipid management, it is considered a secondary priority after initiating SGLT2 inhibitor therapy because it does not confer the broad cardiorenal benefits of SGLT2 inhibitors. [3][2]4

Implementation Strategy

• Initiate dapagliflozin 10 mg once daily (or alternative agents such as empagliflozin 10 mg or canagliflozin 100 mg) in adults meeting the eGFR threshold, as these doses have documented cardiovascular and kidney benefits. [3][4]

Alternative Therapy When SGLT2 Inhibitors Are Contraindicated

• Add a GLP‑1 receptor agonist (e.g., liraglutide, dulaglutide, or semaglutide) as the next best option; this class provides cardiovascular protection, reduces albuminuria, preserves eGFR, promotes weight loss, and carries a low risk of hypoglycemia. [3][1]

Practical Pitfalls to Avoid

• Do not withhold SGLT2 inhibitors solely based on HbA1c levels; their primary advantage in CKD is cardiorenal protection rather than glucose reduction. [3][2]

Management of Hyperglycemia and Kidney Protection in Type 2 Diabetes

Introduction to SGLT2 Inhibitors

• The KDIGO 2020 guidelines recommend SGLT2 inhibitors for patients with type 2 diabetes, CKD, and eGFR ≥30 mL/min/1.73 m² (1A recommendation) 5
• SGLT2 inhibitors reduce the risk of end-stage kidney disease, doubling of serum creatinine, cardiovascular death, and hospitalization for heart failure in patients with diabetic nephropathy and albuminuria >300 mg/day is not included as it has an [ignore ref], however, SGLT2 inhibitors provide potent glucose-lowering, with HbA1c reductions of 0.5-1.0% when added to existing therapy 6, 7
• The American College of Cardiology recommends SGLT2 inhibitors as they reduce major adverse cardiovascular events independent of glucose lowering 6, 7

SGLT2 Inhibitor Selection and Initiation

• Canagliflozin, empagliflozin, or dapagliflozin can be used as alternative SGLT2 inhibitors, which also have documented cardiovascular and kidney benefits 6, 7
• Before initiating the SGLT2 inhibitor, the patient's eGFR must be checked, and if eGFR ≥30 mL/min/1.73 m², the SGLT2 inhibitor can be initiated immediately 5, 8

Metformin Dose Adjustment

• The KDIGO guidelines recommend adjusting the metformin dose based on eGFR: for eGFR ≥60, continue current metformin dose; for eGFR 45-59, reduce to half of maximum dose; for eGFR 30-44, reduce to half of maximum dose and monitor every 3-6 months; and for eGFR <30, discontinue metformin 5, 8

Alternative Therapies

• If SGLT2 inhibitor is contraindicated or not tolerated, add a GLP-1 receptor agonist, such as liraglutide, dulaglutide, or semaglutide, which provide cardiovascular protection, reduced albuminuria, preserved eGFR, weight loss, and low hypoglycemia risk 7, 9

Safety Monitoring

• Within 2-4 weeks of starting SGLT2 inhibitor, assess for volume depletion symptoms, expect a modest, reversible eGFR decline, educate on genital mycotic infection symptoms and diabetic ketoacidosis warning signs, and monitor blood glucose to assess response 6, 7
• Long-term monitoring includes eGFR every 3-6 months if eGFR <60 mL/min/1.73 m², and continuing SGLT2 inhibitor even if eGFR declines, as long-term eGFR preservation occurs with continuation 6, 7, 8, 10